Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides

Neuroscience

Volumn 92, Issue 3, 1999, Pages 1001-1009

  Otano, A ^a   Frechilla, D ^a   Cobreros, A ^a   Cruz Orive, L M ^b   Insausti, A ^b   Insausti, R ^c   Hamon, M ^d   Del Rio, J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^d INSERM   (France)

Author keywords

5 ht6 receptor; Antisense oligonucleotide; Anxiety; Nucleus accumbens; Stereology

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RECEPTOR SUBTYPE; SEROTONIN 6 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SOCIAL INTERACTION; STEREOLOGY;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; IMMUNOHISTOCHEMISTRY; INTERPERSONAL RELATIONS; MALE; MAZE LEARNING; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN;

EID: 0033040488     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00066-4     Document Type: Article

References (56)

1. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends pharmac. Sci. 18:1997;12-18.
2. Altschul S.F., Warren Gish W.M., Myers E.W., Lipman D.J. Basic local alignment search tool. J. molec. Biol. 215:1990;403-410.
3. 3 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology. 117:1995;137-148.
4. Artaiz I., Zazpe A., Del Río J. Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice. Behav. Pharmac. 9:1998;103-112.
5. Batra S., König M.F., Cruz-Orive L.M. Unbiased estimation of capillary length from vertical slices. J. Microsc. 178:1995;152-159.
6. Baumgarten H. G. and Grozdanovic Z. (1997) Anatomy of central serotoninergic projections. In Serotoninergic Neurons and 5-HT Receptors in the CNS (eds Baumgarten H. G. and Göthert M.), Handbook of Experimental Pharmacology. Vol. 129, pp. 41-89. Springer, Berlin.
7. Boess F.G., Martin I.L. Molecular biology of 5-HT receptors. Neuropharmacology. 33:1994;275-317.
8. 6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmac. exp. Ther. 274:1995;173-180.
9. Brændgaard H., Gundersen H.J.G. The impact of recent stereological advances on quantitative studies of the nervous system. J. Neurosci. Meth. 18:1986;39-78.
10. Brett R.R., Pratt J.A. Changes in benzodiazepine-GABA receptor coupling in an accumbens-habenula circuit after chronic diazepam treatment. Br. J. Pharmac. 116:1995;2375-2384.
11. Brown D.A., Kang S.H., Gryaznov S.M., DeDionisio L., Heidenreich O., Sullivan S., Xu X., Nerenberg M.I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. biol. Chem. 269:1994;26,801-26,805.
12. Crow T.J. Molecular pathology of schizophrenia: more than one disease process? Br. med. J. 280:1980;66-68.
13. Chiasson B.J., Armstrong J.N., Hooper M.L., Murphy P.R., Robertson H.A. The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell. molec. Neurobiol. 14:1994;507-521.
14. Chopin P., Briley M. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends pharmac. Sci. 8:1987;383-388.
15. Del Río J. and Lasheras B. (1994) The role of different serotonin receptor subtypes in psychiatric syndromes. In Strategies for Studying Brain Disorders (eds Palomo T. and Archer T.), pp. 239-250. Farrand, London.
16. Duncan G.E., Knapp D.J., Breese G.R. Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res. 713:1996;79-91.
17. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Meth. 2:1980;219-238.
18. File S.E. The contribution of behavioural studies to the neuropharmacology of anxiety. Neuropharmacology. 26:1987;877-886.
19. 6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse. 23:1996;164-173.
20. 6 receptor-like material in the rat central nervous system. Brain Res. 746:1997;207-219.
21. 6 serotonin receptors may reflect psychoactive profile. Molec. Med. 1:1995;398-406.
22. Gokhale A.M. Unbiased estimation of curve length in 3-D using vertical slices. J. Microsc. 159:1990;133-141.
23. Gundersen H.G.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147:1987;229-263.
24. Gundersen H.J.G. Stereology of arbitrary particles. J. Microsc. 143:1986;3-45.
25. Handley S.L., McBlane J.W. 5-HT drugs in animal models of anxiety. Psychopharmacology. 112:1993;13-20.
26. Hoyer D., Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology. 36:1997;419-428.
27. Johansson O., Backman J. Enhancement of immunoperoxidase staining using osmium tetroxide. J. Neurosci. Meth. 7:1983;185-193.
28. Kane J.M., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment resistant schizophrenia. Arch. gen. Psychiat. 45:1988;706-789.
29. 6 serotonin receptor. J. Neurochem. 66:1996;47-56.
30. Ladurelle N., Roques B.P., Dauge V. The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens. J. Neurosci. 15:1995;3118-3127.
31. Michel R.P., Cruz-Orive L.M. Application of the Cavalieri principle and vertical sections method to lung: estimation of volume and pleural surface area. J. Microsc. 150:1988;117-136.
32. 6 receptors in the rat brain. Soc. Neurosci. Abstr. 22:1996;1782.
33. Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Molec. Pharmac. 43:1993;320-327.
34. Moser P.C. An evaluation of the elevated-plus maze test using the novel anxiolytic buspirone. Psychopharmacology. 99:1989;48-53.
35. Murphy D.L. Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes and subsystems. Neuropsychopharmacology. 3:1990;457-471.
36. Pellow S., Chopin P., File S.E., Briley M. Validation of open-closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:1985;149-167.
37. Peters A., Palay S. L. and Webster H. F. (1991) The Fine Structure of the Nervous System, p. 494. Oxford University Press, Oxford.
38. Prather P.L., Rezazadeh S.M., Lane J.D., Rowan G.A., Hooper M.L., Lytle D.A., Emmett-Oglesby M.W., Lal H. Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal. J. Pharmac. exp. Ther. 264:1993;622-630.
39. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmac. exp. Ther. 268:1994;1403-1410.
40. 6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem. biophys. Res. Commun. 193:1993;268-276.
41. Schöbitz B., Pezeshki G., Cristopher-Probst J., Reul J.M.H.M., Skutella T., Stöhr T., Holsboer F., Spanagel R. Centrally administered oligodeoxynucleotides in rats: occurrence of non-specific effects. Eur. J. Pharmac. 331:1997;97-107.
42. 6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes. Naunyn-Schmiedeberg's Arch. Pharmac. 350:1994;356-360.
43. 6 receptors positively coupled to adenylyl cyclase in striatal neurons in culture. NeuroReport. 5:1994;2553-2557.
44. 6 receptors. Br. J. Pharmac. 124:1998;556-562.
45. 6 expression in the rat: functional studies using antisense oligonucleotides. Behav. Brain Res. 73:1996;245-248.
46. 3 receptor antagonists. Neuropharmacology. 32:1993;987-993.
47. Sterio D.C. The unbiased estimation of number and size of arbitrary particles using the disector. J. Microsc. 134:1984;127-136.
48. th IUPHAR satellite meeting on serotonin, Rotterdam, July 1998, pp. 23.
49. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends pharmac. Sci. 15:1994;42-46.
50. Ward R.P., Hamblin M.W., Lachowicz J.E., Hoffman B.J., Sibley D.R., Dorsa D.M. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience. 64:1995;1105-1111.
51. West M.J., Gundersen H.J.G. Unbiased stereological estimation of the number of neurons in the human hippocampus. J. comp. Neurol. 296:1990;1-22.
52. West M.J., Ostergaard K., Andreassen O.A., Finsen B. Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J. comp. Neurol. 370:1996;11-22.
53. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J.R., Neckers L.M. Stability, clearance and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application whitin the central nervous system. Proc. natn. Acad. Sci. U.S.A. 90:1993;4665-4669.
54. Yaida Y., Nowak T.S. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Regul. Pept. 59:1995;193-199.
55. 6 receptor sutype in the rat brain. Life Sci. 62:1998;1473-1477.
56. Zon G. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Molec. Neurobiol. 10:1995;219-229.